| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8668410 | Journal of Clinical Lipidology | 2018 | 43 Pages |
Abstract
Clinically meaningful LDL-C-lowering activity was observed in patients receiving alirocumab who were double heterozygous, compound heterozygous, or homozygous for genes that are causative for FH.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Merel L. MD, Joep C. PhD, Gisle MD, Paul N. MD, MSPH, John J.P. MD, PhD, FESC, Marie T. MD, MSc, Werner MD, Sara MA, PhD, Poulabi PhD, Claudia MD, PhD,